Peter Laing

This inventor holds 7 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignees: United Therapeutics Corporation, Excivion Ltd, Peptide Therapeutics Limited. Active years: 2000-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Peter Laing. Retrieved from https://idiyas.com/inventor/peter-laing-kad6dxqs

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 (Patent Applications = 2)

% Patents Active = 85.7

EPO Patents = 1 (Patent Applications = 6)

Average Co-Inventor Count = 1.1

ph-index = 3

Forward Citations = 31(Granted Patents)

Company Filing History:

4 out of 133

United Therapeutics Corporation

Peptide Therapeutics Limited

patents

Years Active: 2000-2024

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12017989 - Controlled release pharmaceutical formulations (2024-06-25),

2. 11401307 - Glycosylated analogues of Flavivirus E proteins and their use in diagnostic methods (2022-08-02),

3. 11028133 - Modified flavivirus envelope sequences comprising unique glycosylation sites (2021-06-08),

4. 11001551 - Controlled release pharmaceutical formulations (2021-05-11),

5. 10494327 - Controlled release pharmaceutical formulations (2019-12-03),

6. 9758465 - Controlled release pharmaceutical formulations (2017-09-12),

7. 6034066 - Cysteine protease inhibitors for use in treatment of IGE mediated (2000-03-07),

Title: Peter Laing: Innovator in Pharmaceutical Formulations

Introduction

Peter Laing is a notable inventor based in Cambridge, GB. He has made significant contributions to the field of pharmaceutical formulations, holding a total of 7 patents. His work focuses on innovative drug release mechanisms and diagnostic methods related to flavivirus infections.

Latest Patents

Among his latest patents, Laing has developed controlled release pharmaceutical formulations. These formulations include drug release polymer compounds and compositions comprising prostacyclin compounds. Additionally, he has created glycosylated analogues of flavivirus E proteins, which are used in diagnostic methods for detecting anti-flavivirus antibodies and diagnosing flavivirus infections.

Career Highlights

Laing has worked with prominent companies in the pharmaceutical industry, including United Therapeutics Corporation and Excivion Ltd. His expertise in drug formulation and diagnostics has positioned him as a key player in the development of innovative medical solutions.

Collaborations

Laing has collaborated with notable professionals in his field, including Tony Johnson and Terrance Hart. These partnerships have contributed to the advancement of his research and the successful implementation of his inventions.

Conclusion

Peter Laing's contributions to pharmaceutical innovations highlight his role as a leading inventor in the industry. His patents and collaborations continue to influence advancements in drug delivery and diagnostic methods.

Profile summary based on public USPTO records.